You are here: Industry Insights > ADC

News List

Glythera and IONTAS to collaborate for development of multiple antibodies for next-generation Antibo pharmaasia
September 26, 2017
This collaboration will capitalise on the Glythera ADC development expertise and Iontas' experience in antibody discovery services for optimal effect.
UK firms link to develop ADCs for cancer pharmatimes
September 21, 2017
UK groups Glythera and IONTAS are working together on the development of antibody drug conjugates for difficult-to-treat cancers.
Astellas announces wind-down of Agensys research operations biospectrumasia
July 28, 2017
Astellas plans to complete the wind-down of Agensys research operations in the first quarter of calendar 2018.
Morphotek Launches ADC Services Business contractpharma
April 05, 2017
Aligns antibody engineering and clinical development assets into a client-focused ADC business
NBE-Therapeutics Expands Board of Directors by the Appointment of Hans-Peter Gerber b3cnewswire
April 05, 2017
NBE Therapeutics AG, a biopharmaceutical company developing next generation ADC products based on its Transpo-mAb™ antibody platform...
Seattle Genetics gains rights to Immunomedics' experimental cancer drug sacituzumab govitecan firstwordpharma
February 13, 2017
Seattle Genetics agreed to license exclusive global rights to develop, manufacture and commercialise Immunomedics' experimental cancer drug sacituzumab govitecan under a deal potentially worth around $2 billion, the companies announced Friday.
Seattle Genetics Announces Agreement with Immunomedics for Sacituzumab Govitecan, a Promising Late-S americanpharmaceuticalreview
February 13, 2017
Seattle Genetics has announced a development and license agreement with Immunomedics, Inc.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page